Shayna Sarosiek,Christopher T Doughty,Jorge J Castillo
Shayna Sarosiek
Purpose of review: Peripheral neuropathy (PN) is more commonly seen in individuals with monoclonal gammopathies, especially in patients with an IgM monoclonal gammopathy or Waldenström macroglobulinemia. ...
Disparities in Clinical Trial Enrollment- Focus on CAR-T and Bispecific Antibody Therapies [0.03%]
CAR-T和双特异性抗体疗法临床试验登记的差异性分析
Nadia Islam,Laura Budvytyte,Nandita Khera et al.
Nadia Islam et al.
Purpose of review: Recent studies show that unresolved disparities hinder enrollment to clinical trials, equitable distribution of treatments, and impact the generalizability of trials, compromising health outcomes across...
Contemporary Updates in the Prevention and Treatment of Graft-Versus-Host Disease [0.03%]
当前移植物抗宿主病预防和治疗的进展
Sameem Abedin,Mehdi Hamadani
Sameem Abedin
Purpose of review: Graft-versus-host disease (GVHD) is a serious complication after allogeneic HCT. Recently, several pivotal studies have been conducted demonstrating significant improvements in the management of GVHD. H...
Maintenance Therapy Post-Stem Cell Transplantation for Patients with T-Cell Lymphomas [0.03%]
T细胞淋巴瘤自体造血干细胞移植后的维持治疗
Zachary Braunstein,Jonathan E Brammer
Zachary Braunstein
Purpose of review: Given the poor outcomes for peripheral T-cell lymphomas (PTCL), stem cell transplant (SCT) remains an important therapeutic approach. Post-SCT relapse is common and maintenance therapy post-SCT is incre...
K Thaw,C N Harrison,P Sriskandarajah
K Thaw
Purpose of review: The landscape of myelofibrosis (MF) has changed since the discovery of the JAK2 V617F mutation and subsequent development of JAK inhibitors (JAKis). However, treatment with JAKis remain a challenge. In ...
Akhil Rajendra,Vikas Gupta
Akhil Rajendra
Purpose of review: Allogeneic hematopoietic cell transplantation is the only potentially curative treatment for myelofibrosis. This review discusses issues not well-covered by existing guidelines: timing of transplant, pr...
Isabel Farmer,Deepti H Radia
Isabel Farmer
Purpose of review: Since identification of Systemic mastocytosis (SM) as a distinct disease entity by the World Health Organisation (WHO), there has been a wealth of new research in therapeutic targeting of the pathogenic...
Barbara Mora,Cristina Bucelli,Daniele Cattaneo et al.
Barbara Mora et al.
Purpose of review: Myelofibrosis (MF) includes prefibrotic primary MF (pre-PMF), overt-PMF and secondary MF (SMF). Median overall survival (OS) of pre-PMF, overt-PMF and SMF patients is around 14 years, seven and nine yea...
Management of Toxicities Associated with BCMA, GPRC5D, and FcRH5-Targeting Bispecific Antibodies in Multiple Myeloma [0.03%]
靶向BCMA、GPRC5D和FcRH5的双特异性抗体在多发性骨髓瘤治疗中的毒性管理
Darren Pan,Joshua Richter
Darren Pan
Purpose of review: The introduction of bispecific antibodies is one of the most significant recent advances in the treatment of relapsed/refractory multiple myeloma. This review will summarize the management of the toxici...
Approach to the patient with eosinophilia in the era of tyrosine kinase inhibitors and biologicals [0.03%]
酪氨酸激酶抑制剂和生物制剂时代嗜酸性粒细胞增多症患者的诊疗思路
Johannes Lübke,Georgia Metzgeroth,Andreas Reiter et al.
Johannes Lübke et al.
Purpose of review: In this review, we aim to explore the optimal approach to patients presenting with eosinophilia, considering recent advances in diagnostic and therapeutic strategies. Specifically, we focus on the integ...